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There is a limited availability of deceased human organs and cells for the purposes of clinical trans-
plantation. Genetically-engineered pigs may provide an alternative source. Although several immune
barriers need to be overcome, considerable progress has been made in experimental models in recent
years, largely through the increasing availability of pigs with new genetic modiﬁcations.
Pig heterotopic heart graft survival in nonhuman primates has extended for 8 months, with orthotopic
grafts supporting life for almost 2 months. Life-supporting kidney transplants have functioned for almost
3 months. The current barriers are related to coagulation dysfunction between pig and primate that
results in thrombotic microangiopathy and/or a consumptive coagulopathy, which may in part be related
to molecular incompatibilities in the coagulation systems of pigs and primates. Current efforts are
concentrated on genetically-modifying the organ- or islet-source pigs by the introduction of ‘anticoag-
ulant’ or ‘anti-thrombotic’ genes to provide protection from the recipient coagulation cascade and
platelet activation.
Progress with pig islet xenotransplantation has been particularly encouraging with complete control of
glycemia in diabetic monkeys extending in one case for >12 months. Other areas where experimental
data suggest the possibility of early clinical trials are corneal xenotransplantation and pig neuronal cell
xenotransplantation, for example, in patients with Parkinson’s disease.
With the speed of advances in genetic engineering increasing steadily, it is almost certain that the
remaining problems will be overcome within the foreseeable future, and clinical allotransplantation will
eventually become of historical interest only.
 2010 Published by Elsevier Ltd on behalf of Surgical Associates Ltd.1. Introduction
There is a critical and increasing shortage of organs for the
purposes of organ transplantation (Tx). In the USA alone approxi-
mately 110 000 patients are on the waiting list for an organ of one
sort or another, and yet during the current year only approximately
30 000 organswill become available from deceased human donors.
Almost 20 patients waiting for a human organ die each day, i.e.,
almost 7 000 per year.
If islet Tx becomes clinically more successful, as it slowly is, then
the situationwill bemuchmore serious. There are an estimated 2e3
million type 1 diabetic patients taking insulin each day in the USA.
Xenotransplantation (xenoTx), i.e., the transplantation of
organs, tissues, and cells across species, particularly using the pig asene-knockout; IBMIR, instant
od cells; Tx, transplantation.
: þ1 412 624 1172.
er).
Elsevier Ltd on behalf of Surgicalthe source, offers the potential to resolve the critical shortage of
human organs and cells (Table 1).12. History of xenotransplantation
Clinical xenoTx has a long history going back to the 17th century
when clinical blood transfusions were performed from animals.2
Corneal3 and organ4,5 xenoTx were attempted during the 19th
and 20th centuries (Table 2). Since those days, however, experi-
mental xenoTx has advanced signiﬁcantly, largely due to the
availability of pigs genetically-modiﬁed to protect their organs and
cells from the human immune response.3. Pathophysiology of pig organ injury in primates
Unlike alloTx, where the cellular immune response dominates,
following pig organ xenoTx the graft is usually lost within minutes
through an antibody-mediated response.6,7 The innate immune
system, including cells, e.g, macrophages and polymorphs, playsAssociates Ltd.
Table 1
Major advantages of xenotransplantation over allotransplantation.
Unlimited supply of organs, tissues, and cells
Unlimited supply will allow transplantation procedures in ‘borderline’
candidates who might otherwise be declined
Organs available electively
Avoids the detrimental effects of brain death on donor organs
Provides exogenous infection-free sources of organs, tissues, and cells
Obviates the ‘cultural’ barriers to deceased human donation present in
some countries, e.g., Japan
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However, the T cell response to a xenograft is also strong.9,10
3.1. Humoral response
Natural antibodies that develop soon after birth in humans
and Old World nonhuman primates11 recognize speciﬁc galactose
(Gala1,3Gal) antigens on the surface of vascular endothelial
cells12e16 to which they bind, activating complement and initiating
rapid graft destruction, of which vascular thrombosis is a key
factor17e19 (Fig. 1).
This was ﬁrst counteracted by the development of pigs that
expressed a human complement-regulatory protein,20,21 such as
CD55 (DAF),22CD46 (MCP),23,24 and/or CD59,25,26 which greatly
increased the protection of the pig cells to human complement.27
Although survival of grafts from these pigs is signiﬁcantly
extended, this approach is not entirely successful.
When Gala1,3Gal was recognized as being the predominant
antigen to which human anti-pig antibodies are directed,13e15the
development of nuclear transfer (cloning) technology allowed steps
to be taken to delete these carbohydrate antigens from the pig.28e30
In nonhuman primates, the Tx of organs from a1,3-galactosyl-
transferase gene-knockout (GTKO) pigs allowed prolonged graft
survival.31e33
Nevertheless, there are nonGal antigens that, although less
important than Gala1,3Gal, still induce an immune response,
although this is weaker than the response to wild-type pig organ-
s.34e36The nature of these nonGal antigens remains unknown.37-
However, the combination of GTKO and transgenesis for a human
complement-regulatory protein provides an advantage over either
alone, and to a large extent overcomes this weaker antibody-
mediated complement response.38
3.2. Adaptive response
Opinions vary slightly as to the relative strengths of the primate
T cell response to wild-type pig cells and to allogeneic cells.9,10
However, the response to GTKO cells is weaker than to wild-type
pig cells, and is similar to that to human cells.10
If, after pig organ Tx in a nonhuman primate, the immunosup-
pressive therapy is inadequate and a T cell-dependent elicitedTable 2
Summary of clinical xenotransplantation of organs in the 20th century.*
Donor n Survival
Kidney - Primate (30) 1 daye9 months
Non-Primate (3) 3e9 days
Heart - Primate (5) <1e20 days
Non-Primate (4) <1 day
Liver-Primate (11) <1e70 days
Non-Primate (1) <2 days
*Data from Taniguchi S, Cooper, DKC. Ann R Coll Surg Engl. 1997;79:13-19.antibody response develops, the graft almost invariably fails
from acute humoral xenograft rejection.39 However, this can also
result from inadequate suppression of natural anti-pig antibody
production.8
Efforts are being made to modify pigs to express an immuno-
suppressive gene, such as CTLA4-Ig, and thus induce local immu-
nosuppression around the graft, and reduce the need for exogenous
immunosuppressive therapy in the recipient. Pigs expressing high
levels of porcine CTLA4-Ig have been produced but, in fact, have
proven too successful in that the levels of soluble CTLA4-Ig
measured in their blood were many times higher than the thera-
peutic level40; as a result, these pigs were to some extent immu-
noincompetent, and developed troublesome infections.
Nevertheless, the expression of porcine CTLA4-Ig signiﬁcantly
reduced the primate cellular response to porcine cells (Hara H,
manuscript in preparation).
An alternative approach to reducing the primate cellular
response to the pig organ is the production of dominant-negative
swine leukocyte antigen (SLA) class II transactivator (CIITA) trans-
genic pigs. Variants of the CIITA gene were constructed to interfere
with the expression of class II genes (Dai Y et al, unpublished), and
CIITA dominant-negative pigs were produced by cloning. These pigs
have normal lymphocyte subsets and T cell proliferative responses,
but SLA class II expression after cytokine stimulation is almost
completely suppressed.41 After cross-breeding with GTKO/CD46
pigs, these pigswill provideorgans that should have ahighdegree of
resistance to both the humoral and cellular xenoreactive responses.
3.3. Coagulation dysregulation
More recently, survival of a pig organ transplanted into
a nonhuman primate has been limited, not through the immune
response directly, but through the development of a thrombotic
microangiopathy in the vessels of the graft (particularly seen after
heart xenoTx)31,32,42,43 and/or a consumptive coagulopathy in the
recipient of the graft (particularly seen after kidney xenoTx)
(Fig. 2).4446 This observation supports the current opinion that pig
cardiac and renal grafts respond in different ways after XTx.47 The
pathophysiology behind these complications is complex, and may
be initiated by antibody binding to the vascular endothelium,
thus activating the endothelium,48,49 but is certainly increased by
molecular incompatibilities between the pig and primate coagu-
lation systems.50e53Increasingly, therefore, the efforts of the
genetic engineers are being directed to insert human ‘anticoagu-
lant’ or ‘anti-thrombotic’ genes into GTKO pigs already transgenic
for a human complement-regulatory protein.
3.4. Graft vasculopathy (chronic rejection)
In long-surviving heart transplants (>3 months), chronic graft
vasculopathy has been reported,31,32,42,54 as it was in the early days
of alloTx.
3.5. Sensitization
The data available to date indicate that allosensitized humans
will be at no greater risk of humoral rejection of a GTKO pig organ
or cell graft than other humans.34,55 Furthermore, sensitization to
a failed pig organ or islet graft will not prohibit subsequent organ or
islet alloTx.56
4. Pig-to-primate organ transplantation - current results
GTKO/CD46 pig hearts transplanted heterotopically have
been reported to function for 6e8 months.31,32,57 Orthotopically
Fig. 1. Summary of the known immunologic barriers to pig-to-primate heart transplantation. (Reproduced with permission from Zhu X, et al, J Heart Lung Transplant 2007.)
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baboons for periods approaching 2 months,58 and life-supporting
CD55-transgenic59 and GTKO33,60 pig kidney transplants have
functioned adequately for periods of 2e3 months. Survival of pig
liver grafts is limited by the rapid development of a profoundthrombocytopenia in the recipient (Fig. 3).61 This leads to
internal hemorrhage in multiple native organs. The fragile
structure of the pig lung makes it much more susceptible to
primate immune-mediated injury,62e64 and graft survival is
limited to hours.
Fig. 2. Correlation between platelet count and ﬁbrinogen level (indicating the development of a consumptive coagulopathy) and tissue factor expression on platelets and peripheral
blood mononuclear cells (PBMC) in a representative baboon following GTKO/CD46 pig-to-baboon kidney transplantation. The baboon was euthanized with a functioning graft
(serum creatinine 2.0 mg/dL) on day 16. Microscopic examination of the kidney at necropsy showed no or minimal deposition of IgM, IgG or C3, no cellular inﬁltrates, but some
deposition of ﬁbrin. (Data from Lin CC, et al. Am J Transplant 2010.)4.1. Physiology
Even if the immune barriers are overcome, will the organ carry
out all of the functions of the native organ? There is little evidence
as yet,65 but the fact that pig hearts havemaintained life in baboons
for several weeks suggests that cardiac function will be adequate.
Pig renal function appears satisfactory in most respects, but
proteinuria has been documented in all nonhuman primates with
pig kidneys; whether this is initiated by an immune process or not
remains uncertain. The pig liver functions relatively normally in the
nonhuman primate host,66 though follow-up has been limited.
Current evidence is that geneticmanipulations to protect the pig
organ from coagulation dysfunction, or the administration of drugs
that might have the same effect, is required before consideration
can be given to clinical trials.53Fig. 3. (A) Blood glucose, serum porcine-C peptide level, and exogenous insulin
requirements in a streptozotocin-induced diabetic monkey recipient after trans-
plantation of islets from an adult CD46-transgenic pig. (B) Insulin immunostaining of
liver section in the same monkey >1 year after islet transplantation. (Data from van der
Windt DJ, et al. Am J Transplant 2009.)5. Pig-to-primate islet transplantation e current results
At least four groups have obtained survival of pig islet grafts
with control of glycemia in diabetic monkeys for periods in excess
of 3e6 months,67e70 and in one case for more than one year
(Fig. 4).70 Encapsulation of the islets in the absence of immuno-
suppressive therapy has shown encouraging results in one series.69
When non-encapsulated islets are transplanted into the portal vein,
there is an initial massive loss of islets e the so-called ‘instant
blood-mediated inﬂammatory reaction’ (IBMIR).71,72 GTKO/CD46
pigs are becoming available that express tissue factor pathway
inhibitor and CD39 in the islets, and it is hoped that these will
induce some resistance to IBMIR. Islet xenoTx, therefore, may
provide the ﬁrst opportunity for a meaningful clinical trial.
An alternative approach would be to transplant the islets into
a site other than the portal vein, which is the site currently used for
all clinical alloTx.70
There is some evidence that neonatal islets are more resistant to
injury than adult islets.73 In xenoTx this would have the advantage
that the genetically-engineered islet-source pigs could be used
within days of birth, and therefore would not need to be housed for
several months or years until large enough to be used as sources of
adult pig islets, greatly reducing the costs involved.
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have been investigated by Casu74 who concluded that there are
differences in glucose metabolism between cynomolgus monkeys
and pigs that magnify the difﬁculties of obtaining normoglycemia
in monkeys with porcine islet transplants. Fortunately, the data
suggest that it should be easier for normoglycemia to be obtained
after porcine islet Tx into humans.6. Corneal xenotransplantation
XenoTx could provide an unlimited source of corneas for
patients with corneal blindness.3 Although the number of deceased
human donors available in most of the western world is adequate
for this purpose, there is a very signiﬁcant shortage of human
corneas in many parts of the world (Table 3).
In vivo studies in nonhumanprimates by Pan75 and Oh76 indicate
that evenwild-type (unmodiﬁed) pig corneas remain functional for
severalmonthswhen treated locallywith corticosteroids. Current in
vitro experimental evidence from our own group indicates thatFig. 4. (A) Platelet counts in 11 baboons during the ﬁrst 7 days after orthotopic GTKO/CD46
orthotopic GTKO/CD46 pig liver transplantation (Reproduced with permission from Ekser Bcorneas from GTKO/CD46 pigs show considerable resistance to the
human immune response.77 With new genetic modiﬁcations being
introduced, it is likely that, from an immune perspective, pig
corneas will soon be comparable to human corneas. They also
appear to be comparable to a human cornea from a biomechanical
perspective.37. Neuronal cell xenotransplantation
The potential of pigs as sources of cells that might correct
various neurodegenerative conditions is also being explored. For
example, there is considerable potential for the Tx of pig dopamine-
producing cells in conditions such as Parkinson’s disease.78
Preliminary reports from Cozzi and his colleagues indicate signiﬁ-
cant improvement in motor function in monkeys in which
a Parkinson-like condition has been induced, and in which cells
from the ventral mesencephalon of pig embryos have been
implanted. The number of patients who would beneﬁt from this
form of therapy is clearly considerable.pig liver transplantation. (B) Platelet counts in two baboons during the ﬁrst 5 h after
, et al. Am J Transplant 2010.)
Table 3
Estimated numbers of corneal allotransplants carried out in 2008 and numbers of
patients awaiting corneal transplantation in selected countries*
Country Estimated number
of cases per year
Waiting list
United States of America 41,652 Saturated
United Kingdom 2,711 500
South Africa** 330 1,884
India 15,000 300,000
China 101 4,000,000
Taiwan 263 637
Korea 480 3,630
Japan 1,634 2,769
Australia 1,096 Saturated
*Based on Eye Bank data in individual countries and personal communications.
**In sub-Saharan Africa, the number of corneal transplants carried out annually has
been falling for several years because of the high incidence of human immunode-
ﬁciency virus (HIV)-positivity in the potential donor population.
D.K.C. Cooper, D. Ayares / International Journal of Surgery 9 (2011) 122e129 1278. The pig as a source of red blood cells (RBCs) for clinical
transfusion
There is an immense need for an alternative source of RBCs in
many countries, particularly where the incidence of HIV-positivity
is high in the population. RBCs from genetically-modiﬁed pigs
have the potential to resolve this problem. Most characteristics of
pig RBCs are similar to those of human RBCs.79e81
RBCs from GTKO pigs are superior to human ABO-incompatible
red blood cells, but are not yet comparable to ABO-compatible
RBCs.82 With the current technology that has been used to genet-
ically-modify pigs, transgenes (e.g., those for complement-regula-
tory proteins) are not expressed in pig RBCs. It is likely that, if these
transgenes can be directed to the pig RBCs using perhaps a hemo-
globin or similar promoter, then pig RBCs may well be rendered
comparable to ABO-compatible human RBCs for the purposes of
transfusion.
9. Regulation of clinical xenotransplantation
With regard to the potential transfer of an infectious microor-
ganism from the donor,83 there have been particular concerns
about the transfer of porcine endogenous retroviruses with the
organ or cells to the human recipient, as these form an integral part
of each cell. However, the associated risks are now considered to be
small.84 Furthermore, if need be, these viruses could be prevented
from activation by siRNA technology that has recently been
reported.85e87
Nevertheless, for this reason and others, clinical xenoTx will
require oversight by regulatory authorities, e.g., the Food and Drug
Administration in the USA. Guidelines have been published in
several countries88,89 and by the World Health Organization90 that
those carrying out clinical trials will be required to follow. In
particular, archiving of tissues and blood from source pigs and
human recipients will be mandatory to enable retrospective
investigation, if ever indicated. Ethical guidelines relating to clinical
xenoTx have also been published.91
If necessary, the genetically-engineered pigs that will be
required to provide corneas, cells, or RBCs can be housed and bred
under ideal circumstances in the more developed countries, with
the corneas, cells, or RBCs being shipped to the less well-developed
countries where they would be used.
10. Conclusions
Processed tissues (with no living cells), such as small intestinal
submucosa, bone chips, ligaments, tendons, skin, and heart valvesfrom wild-type pigs are already being used extensively in clinical
practice. Steps are underway to replace the wild-type pigs for this
purpose by GTKO pigs to which there is a reduced inﬂammatory
response.92
Nevertheless, xenoTx’s main impact will be when islets, organs,
or other living tissues or cells can be used successfully in clinical
practice. We are gradually drawing closer to the time when clinical
trials of pig corneal, neuronal, or islet xenoTx will become fully
justiﬁed. Trials of pig organ xenoTx will take a little longer until the
current problems, outlined above, can be resolved. Nevertheless,
with the speed of advances in genetic engineering increasing
steadily, it is almost certain that the remaining problems will be
overcome within the foreseeable future, and clinical alloTx will
eventually become of historical interest only.
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